Iroko Pharmaceuticals, which is developing high-efficacy, low-dose NSAID therapeutics, withdrew its plans for an initial public offering on Wednesday citing poor market conditions. The Philadelphia, PA-based company was founded in 2007 and booked $10 million in sales for the 12 months ended March 31, 2013. Iroko Pharmaceuticals initially filed confidentially on March 1, 2013. Jefferies & Co., William Blair and Canaccord Genuity were set to be the joint bookrunners on the deal.
